Avation Medical

Executive Summary

Avation Medical is a privately held medical device and digital health company headquartered in Columbus, Ohio, focused on developing patient-friendly, wearable neuromodulation systems. Founded in 2016, the company's flagship product, the Vivally® System, is an FDA-cleared, at-home treatment for Overactive Bladder (OAB) and urge urinary incontinence. Vivally delivers non-invasive tibial nerve stimulation via a wearable patch, offering a convenient alternative to clinic-based therapies or surgical implants. This addresses a significant unmet need, as OAB affects millions of adults and current treatments often suffer from poor adherence or invasive procedures. Avation's approach combines hardware, software, and digital coaching to improve patient compliance and outcomes. The company operates in the competitive neuromodulation market, but Vivally's differentiated home-use design positions it to capture share from office-based therapies and implantable devices. With no disclosed funding or valuation, Avation likely requires capital to scale commercial operations, expand reimbursement, and pursue new indications. Key upcoming catalysts include broadening insurance coverage, which could drive adoption, and potential clinical data supporting label expansion. If successful, Avation could become a leading player in the growing market for non-invasive pelvic health therapies. However, as a private company with limited public information, execution and funding risks remain.

Upcoming Catalysts (preview)

• H2 2026Expansion of Medicare and Private Payer Reimbursement Coverage70% success
• 2027Publication of Additional Clinical Data Supporting Label Expansion (e.g., Fecal Incontinence)50% success
• Q1 2027Strategic Partnership or Distribution Agreement with Larger Urology/Pelvic Health Player40% success